RxDoctor Payments Data

Aron Simkins, MD

Hematology & Oncology · Miami Beach, FLNPI 1093197931

Payments from drug & device makers

$63,046in general payments, 2019–2025

Across 1,113 payments — averaging $56.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$41K
  • Johnson & Johnson$2K
  • Bristol Myers Squibb$1K
  • AstraZeneca$1K
  • Merck$1K
  • Pfizer$1K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$2,8104%
  • Speaking & faculty fees$33,60053%
  • Travel & lodging$3,2745%
  • Food & beverage$23,21837%
  • Education$1440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.74$41,011
Johnson & Johnson(2 entities)118$1,617
Bristol Myers Squibb75$1,469
AstraZeneca(2 entities)52$1,412
Merck59$1,226
Pfizer59$1,151
Novartis67$1,123
Daiichi Sankyo Inc.35$1,019
Astellas Pharma US Inc37$745
Genentech USA, Inc.24$645
AbbVie23$571
Incyte Corporation18$506
Sanofi19$465
GSK19$459
Beigene USA, Inc.23$449
Sumitomo Pharma America, Inc.18$424
Array Biopharma Inc25$420
Takeda Pharmaceuticals U.S.A., Inc.19$416
Tempus AI, Inc9$406
Bayer23$381
Myriad Genetic Laboratories, Inc.12$337
Boehringer Ingelheim13$331
E.r. Squibb & Sons, L.L.C.16$304
Amgen14$294
Taiho Oncology, Inc.12$286
Lilly USA, LLC13$267
Exelixis Inc.9$266
EMD Serono, Inc.13$256
Regeneron Healthcare Solutions, Inc.8$252
Deciphera Pharmaceuticals Inc.11$234
Ipsen Biopharmaceuticals, Inc13$228
Beone Medicines USA, Inc.10$225
Seagen Inc.14$223
Jazz Pharmaceuticals Inc.7$211
Adaptive Biotechnologies Corporation10$206
Sobi, Inc10$203
Springworks Therapeutics, Inc.9$195
Sirtex Medical Inc2$191
Genmab U.S., Inc.8$181
Rigel Pharmaceuticals, Inc.6$173
Mirati Therapeutics, Inc.9$169
Servier Pharmaceuticals LLC6$139
Stemline Therapeutics Inc.8$139
Pharmacosmos Therapeutics Inc.6$110
Intuitive Surgical1$94
ADC Therapeutics America, Inc.5$94
Geron Corporation4$93
Blueprint Medicines Corporation5$87
Sanofi US Services Inc.1$83
Pharmacyclics LLC, An Abbvie Company4$80
AVEO Pharmaceuticals, Inc.3$79
Tersera Therapeutics LLC3$76
Foundation Medicine, Inc.4$76
Dendreon Pharmaceuticals LLC3$75
Morphosys, US Inc.3$71
Epizyme, Inc.3$69
Caris MPI, Inc.3$66
CTI Biopharma Corp.3$58
Puma Biotechnology, Inc.3$57
Kyowa Kirin, Inc.2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,046 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$69,289
Medicare patients
257
Services billed
941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide106$1,501,622
NubeqaDarolutamide76$997,190
RevlimidLenalidomide40$710,568
LenvimaLenvatinib Mesylate20$490,296
TagrissoOsimertinib Mesylate23$385,369
ErleadaApalutamide26$367,675
CabometyxCabozantinib S-Malate13$336,572
BrukinsaZanubrutinib22$241,208
SprycelDasatinib13$224,995
KrazatiAdagrasib13$203,838
Abiraterone Acetate85$130,453
EliquisApixaban42$47,013
OrgovyxRelugolix15$43,819
XareltoRivaroxaban23$28,368
CreonLipase/Protease/Amylase11$14,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$745$1,501,622106 claims
BayerNubeqa$381$997,19076 claims
Bristol Myers SquibbRevlimid$1,469$710,56840 claims
Eisai Inc.Lenvima$41,011$490,29620 claims
Johnson & JohnsonErleada, Xarelto$1,617$396,04249 claims
AstraZenecaTagrisso$1,412$385,36923 claims
Exelixis Inc.Cabometyx$266$336,57213 claims
Beigene USA, Inc.Brukinsa$449$241,20822 claims
E.r. Squibb & Sons, L.L.C.Sprycel$304$224,99513 claims
Mirati Therapeutics, Inc.Krazati$169$203,83813 claims
PfizerEliquis$1,151$47,01342 claims
Sumitomo Pharma America, Inc.Orgovyx$424$43,81915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →